Ambrilia Biopharma Inc., a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today the appointment of two new members to its Board of Directors. Joining the Board are Mr. Joseph J. Krivulka, President and Chief Executive Officer of Triax Pharmaceuticals LLC (U.S.) and a former executive at Mylan Laboratories (U.S.), and Mr. Stephen G. Sudovar, former President and Chief Executive Officer of Elusys Therapeutics Inc. (U.S.) and former President of Roche Laboratories (U.S.).
